FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081657110> ?p ?o ?g. }

• W3081657110 abstract "Introduction: Neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumors (MPNSTs) are malignant sarcomas occurring in approximately 15% of NF1 patients and always develop within benign precursor lesions (plexiform neurofibromas). The mortality caused by these tumors is high, approaching 100% in patients with unresectable, metastatic or recurrent disease. Targeted inhibition of the MAP kinase (MAPK) pathway has been attempted in clinical trials using MEK inhibitors (MEKi). While emerging data demonstrate effective tumor growth inhibition in benign plexiform neurofibromas, MEK inhibition blocks MPNST progression only to a limited extent. Combination strategies targeting both the MAPK and PI3K/AKT pathways (horizontal inhibition) have had limited clinical success due to excessive toxicities which precludes delivery of optimal therapeutic concentrations. Thus, novel approaches and complementary treatment strategies that are tolerable and prevent adaptive resistance mechanisms in NF1 MPNST are urgently needed. Methods: We have succeeded in establishing orthotopic in vivo models (patient-derived human xenografts-PDXs and genetically engineered mouse models- GEMMs) via implantation of tumor cells into the sciatic nerve, an approach that is critical, because it preserves the tumor microenvironment. Furthermore, we have optimized MPNST culture conditions, allowing us to establish robust primary cultures of MPNSTs while retaining key biological features of the original tumors. Summary of findings: Using this preclinical testing platform, we demonstrate that - 1. A feedback loop mediated by induction of receptor tyrosine kinase (RTK) signaling becomes hyperactivated upon MEK inhibition (MEKi). This subsequently activates the MAPK pathway to such an extent that MEKi alone is unable to completely block signaling to ERK, thereby maintaining tumor proliferation. 2. SHP2 is a protein tyrosine phosphatase (PTP) that functions as a positive signal transducer, acting between RTKs and RAS and thus, functions as physiological mediator for RAS activation. A treatment paradigm where MEKi is combined with SHP099, an allosteric SHP2 inhibitor to counteract the rebound increase in RTK mediated signaling to RAS-MEK-ERK results in effective attenuation of MEK-ERK signaling. In vivo studies demonstrate that the drug combination exhibits synergistic effects on tumor growth inhibition and significantly prolongs survival. 3. SHP099 disrupts a functional complex (SOS1/GRB2) which is essential to RAS-GTP loading and inhibits RAS-mediated downstream MAP kinase signaling in NF1 MPNST. Conclusions - Our results provide a mechanistic context for SHP29s precise role in the regulation of RAS-GTP and demonstrate that SHP2i can prevent adaptive resistance to MEKi. Given that allosteric SHP2 inhibitors are currently in clinical trials (NCT03114319), our studies can be rapidly translated into a clinical trial to evaluate a combination of SHP2i and MEKi as a novel treatment approach in NF1-MPNSTs. Citation Format: Sameer Farouk Sait, Kwan Tang, Rebecca Brown, Daochun Sun, Xunhua Xie, Benjamin Neel, Luis Parada. Allosteric inhibition of SHP2 prevents adaptive resistance to MEK inhibition in neurofibromatosis type 1 associated malignant peripheral nerve sheath tumors [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1889." @default.
• W3081657110 created "2020-09-08" @default.
• W3081657110 creator A5005276553 @default.
• W3081657110 creator A5008490037 @default.
• W3081657110 creator A5028204025 @default.
• W3081657110 creator A5046103284 @default.
• W3081657110 creator A5061899406 @default.
• W3081657110 creator A5065414178 @default.
• W3081657110 creator A5069778809 @default.
• W3081657110 date "2020-08-13" @default.
• W3081657110 modified "2023-10-15" @default.
• W3081657110 title "Abstract 1889: Allosteric inhibition of SHP2 prevents adaptive resistance to MEK inhibition in neurofibromatosis type 1 associated malignant peripheral nerve sheath tumors" @default.
• W3081657110 doi "https://doi.org/10.1158/1538-7445.am2020-1889" @default.
• W3081657110 hasPublicationYear "2020" @default.
• W3081657110 type Work @default.
• W3081657110 sameAs 3081657110 @default.
• W3081657110 citedByCount "0" @default.
• W3081657110 crossrefType "proceedings-article" @default.
• W3081657110 hasAuthorship W3081657110A5005276553 @default.
• W3081657110 hasAuthorship W3081657110A5008490037 @default.
• W3081657110 hasAuthorship W3081657110A5028204025 @default.
• W3081657110 hasAuthorship W3081657110A5046103284 @default.
• W3081657110 hasAuthorship W3081657110A5061899406 @default.
• W3081657110 hasAuthorship W3081657110A5065414178 @default.
• W3081657110 hasAuthorship W3081657110A5069778809 @default.
• W3081657110 hasConcept C105702510 @default.
• W3081657110 hasConcept C126322002 @default.
• W3081657110 hasConcept C142724271 @default.
• W3081657110 hasConcept C166342909 @default.
• W3081657110 hasConcept C170493617 @default.
• W3081657110 hasConcept C185592680 @default.
• W3081657110 hasConcept C2778984943 @default.
• W3081657110 hasConcept C3018498973 @default.
• W3081657110 hasConcept C46762472 @default.
• W3081657110 hasConcept C502942594 @default.
• W3081657110 hasConcept C71924100 @default.
• W3081657110 hasConceptScore W3081657110C105702510 @default.
• W3081657110 hasConceptScore W3081657110C126322002 @default.
• W3081657110 hasConceptScore W3081657110C142724271 @default.
• W3081657110 hasConceptScore W3081657110C166342909 @default.
• W3081657110 hasConceptScore W3081657110C170493617 @default.
• W3081657110 hasConceptScore W3081657110C185592680 @default.
• W3081657110 hasConceptScore W3081657110C2778984943 @default.
• W3081657110 hasConceptScore W3081657110C3018498973 @default.
• W3081657110 hasConceptScore W3081657110C46762472 @default.
• W3081657110 hasConceptScore W3081657110C502942594 @default.
• W3081657110 hasConceptScore W3081657110C71924100 @default.
• W3081657110 hasLocation W30816571101 @default.
• W3081657110 hasOpenAccess W3081657110 @default.
• W3081657110 hasPrimaryLocation W30816571101 @default.
• W3081657110 hasRelatedWork W2139974530 @default.
• W3081657110 hasRelatedWork W2146586978 @default.
• W3081657110 hasRelatedWork W2433467781 @default.
• W3081657110 hasRelatedWork W2614602025 @default.
• W3081657110 hasRelatedWork W2908340616 @default.
• W3081657110 hasRelatedWork W4298439752 @default.
• W3081657110 hasRelatedWork W4321060081 @default.
• W3081657110 hasRelatedWork W4361956518 @default.
• W3081657110 hasRelatedWork W4361956568 @default.
• W3081657110 hasRelatedWork W4361956569 @default.
• W3081657110 isParatext "false" @default.
• W3081657110 isRetracted "false" @default.
• W3081657110 magId "3081657110" @default.
• W3081657110 workType "article" @default.